Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 10/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | TEC | P42680 | 1/20 | 0.42 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 3/20 | 0.41 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
| ▸ | BRD2 | P25440 | 1/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.40 |
| ▸ | STAT6 | P42226 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19921150 | 0.84 | PLK1 (0.46) | IRAK4PLK1EGFRSYKSTAT6 | |
| SCHEMBL19921152 | 0.82 | EGFR (0.50) | EGFR | |
| SCHEMBL19921105 | 0.81 | LMNA (0.44) | BRD4LMNATP53TSHRMAPK1 | |
| SCHEMBL19929900 | 0.80 | MAPK1 (0.52) | IRAK4BRD4SRCLMNATP53 | |
| SCHEMBL19921145 | 0.78 | DCLK1 (0.43) | IRAK4PLK1EGFRMAPK1SYK | |
| SCHEMBL19921167 | 0.77 | PTK2 (0.51) | IRAK4BRD4EGFR | |
| SCHEMBL22730041 | 0.77 | IRAK4 (0.45) | IRAK4BRD4PLK1EGFRSYK | |
| SCHEMBL21099506 | 0.77 | IRAK4 (0.53) | IRAK4BRD4EGFRSRCTEC | |
| SCHEMBL19921085 | 0.77 | PTK2 (0.56) | EGFR | |
| SCHEMBL19921195 | 0.76 | STAT6 (0.46) | IRAK4SRCSYKSTAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3290420-B1 | PYRIMIDINE PYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | UNIV XIAMEN (CN) | 2020-12-09 | — | — | EP | claimed |
| US-20180312508-A1 | PYRIMIDOPYRROLE COMPOUNDS, METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | XIAMEN UNIVERSITY (CN) | 2018-11-01 | — | — | US | claimed |
| EP-3290420-A1 | PYRIMIDINE PYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | Xiamen University (CN) | 2018-03-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312508-A1 | PYRIMIDOPYRROLE COMPOUNDS, METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | TPMT, DHPS, TYMP | IRAK4 2164/4885BRD4 2933/4885PLK1 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.